News

The all-cash deal between Catalent and Paragon, which was signed in April 2019, was completed after meeting of customary closing conditions such as the expiration of the waiting

These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference. The trial compared Symbicort Turbuhaler with

In children, SBS is a life-threatening, chronic, and rare malabsorption disorder resulting from surgical removal of a large portion of the intestine, which is typically due to congenital

Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in

Depatux-M fails to meet objectives in INTELLANCE-1 study The biopharma company arrived at the decision after finding that the late-stage INTELLANCE-1 study did not meet primary endpoint of

The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs). With more than 400 employees, the

The acquisition, subject inter alia to Realm Shareholder approval, is intended to be implemented by means of a UK Court-sanctioned scheme of arrangement under Part 26 of the

The latest approval for Fragmin is for the blood thinner to be used for reducing symptomatic venous thromboembolism (VTE) in pediatric patients, aged one month and older. The

B7451012 was a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over 12